A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson's Disease

Investigator: William Ondo, MD

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT03655236


Protocol Number: Pro00021539


This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for subjects who have completed week 40 of Part 1. Patients can choose to participate in Part 2 of the study. The extension study was designed to evaluate the safety and efficacy of the study drug at 76 weeks.
More to Explore